TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03924180

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement for PKU patients
Description: For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement for PKU patients
Description: For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.
Study: NCT02148978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: The participants in this study will undergo an OGTT at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin at a dose between 2.5- 5mg a day. After 6 weeks of treatment the participants will return to perform a second OGTT.
Study: NCT03411499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early surgery
Description: Surgery within 72 hours from endocarditis diagnosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Delayed surgical intervention or medical treatment according to the current guidelines
Study: NCT03379766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Successor of Phonak Audéo B-Direct
Description: The successor of Phonak Audéo B-Direct will be fitted to the participants indivudal hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak Audéo B-Direct
Description: The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
Study: NCT02008695

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: adult microfinance
Description: Female piglet provided to household member. Participants agrees to repay participants' loan by giving two piglets (one to repay the loan and one for the interest on the loan) to the association from the first litter of piglets (on average 6-12 piglets). These piglets are then given to other village member households

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Youth microfinance only
Description: One child (10-15 years) receive rabbits loan. The child is mentored by microfinance and community mentors. The child repays the loan to program and other children in the family and community are provided a loan from the repayment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: youth and adult micro finance
Description: One child and adult member of household receive animal loan. The child and adult are mentored and repayment of the loan to the program is provided and the repayment animal is provided to other members of the community
Study: NCT01419392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: 25 mg orally, 4 times per day for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: orally, 4 times per day for 21 days
Study: NCT02079350

Intervention type: DRUG
Intervention: %6 HES and %4 Gelofusine

Intervention type: DRUG
Intervention: %6 HES and %4 Gelofusine
Study: NCT04027530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Description: Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ertugliflozin 15 mg
Description: Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks
Study: NCT00905983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Docetaxel
Description: Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
Study: NCT04275739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Episodic Future Thinking
Description: Brief Academic goal related EFT intervention involving desirable outcomes of current academic goals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vivid Memory Task
Description: Matched for time control task involving recall of vivid memories of distinct events/actions from a children's story
Study: NCT04111120

Intervention type: DIAGNOSTIC_TEST
Intervention: SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI
Description: Coagulation assessment using heparinase treated SONOCLOT

Intervention type: DIAGNOSTIC_TEST
Intervention: SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI
Description: Coagulation assessment using heparinase treated SONOCLOT
Study: NCT01157104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX320
Description: IDX320 400 mg in tablets (8x50 mg) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX320
Description: IDX320 400 mg in tablets (8x50 mg) administered orally once daily
Study: NCT05852782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue light therapy
Description: Participants will be exposed to blue light for one hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red light therapy
Description: Participants will be exposed to re light for one hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Darkness
Description: Participants will be in complete darkness for one hour
Study: NCT03126188

Intervention type: DRUG
Intervention: Venlafaxine
Description: Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
Study: NCT01870999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole IM depot
Description: Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
Study: NCT00910858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 5-mg capsules for oral administration
Study: NCT01157104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 100 mg in capsules (2x50 mg) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 100 mg in capsules (2x50 mg) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184 placebo
Description: IDX184 matching placebo in capsules administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDX184 placebo
Description: IDX184 matching placebo in capsules administered orally once daily
Study: NCT01870999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole IM depot
Description: Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole IM depot
Description: Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole tablets
Description: Aripiprazole tablets 10 mg once daily in the morning for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole tablets
Description: Aripiprazole tablets 10 mg once daily in the morning for 14 days.
Study: NCT01522976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01870999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole tablets
Description: Aripiprazole tablets 10 mg once daily in the morning for 14 days.
Study: NCT03195699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Oral capsule
Study: NCT01522976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT03838549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic mastectomy with immediate breast reconstruction
Description: It is an endoscopic approach for prophylactic mastectomy using an axillary single port
Study: NCT00146835

Intervention type: BIOLOGICAL
Intervention: Pediarix
Description: 1 or more injections

Intervention type: BIOLOGICAL
Intervention: Licensed DTPa containing vaccine
Description: 1 or more injections

Intervention type: BIOLOGICAL
Intervention: Licensed DTPa containing vaccine
Description: 1 or more injections

Intervention type: BIOLOGICAL
Intervention: Prevnar®: (Wyeth)
Description: Concomitant vaccination

Intervention type: BIOLOGICAL
Intervention: Prevnar®: (Wyeth)
Description: Concomitant vaccination

Intervention type: BIOLOGICAL
Intervention: Prevnar®: (Wyeth)
Description: Concomitant vaccination
Study: NCT04126226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech-language guidance
Description: Speech-language guidance for speech enhancement and on food management in terms of consistency, volumes, utensils and temperature, beyond the care for safe and efficient swallowing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy exercises for swallowing
Description: Use of lip exercises and facial muscles, laryngeal elevation maneuver and airway protection technique, 5 repetitions 3 times a day for a month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy exercises for speech
Description: Use of over-articulation technique and glottal firmness exercise, 5 repetitions 3 times a day for a month.
Study: NCT04139395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Citrate PET/MRI
Description: Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 67Ga-Citrate SPECT
Description: 67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Imaging with 68Ga-Citrate PET/MRI
Study: NCT01157104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX320 placebo
Description: IDX320 matching placebo in tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDX320 placebo
Description: IDX320 matching placebo in tablets administered orally once daily
Study: NCT02073929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide for 26 weeks
Description: GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo s.c. daily for 26 weeks
Study: NCT04139395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Imaging with 68Ga-Citrate PET/MRI
Study: NCT02807038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung function test
Description: Pregnant woman use the individual passive sampler 15 days before the spirometry test at each trimester
Study: NCT03768908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate + Amodiaquine
Description: Three day treatment with Artesunate + Amodiaquine, co-administered, a dose a day under direct observation
Study: NCT01019759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary vein isolation
Description: The off-pump beating heart ablation procedure is performed. Using a Microwave (MW) energy ablation tool (Microwave generator by Guidant), epicardial ablation line isolating the pulmonary veins are applied during open heart surgery
Study: NCT03390972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (NaCl 0.9%) TCI infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine TCI 0.6 ng/ml and 1.2 ng/ml
Study: NCT01489436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-port cholecystectomy
Description: In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. This trocar permits simultaneous introduction of multiple instruments, including a 5-mm flexible-tip laparoscope. Standard 5-mm instruments will be used for retraction and dissection. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four-port laparoscopic cholecystectomy
Description: The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder.
Study: NCT02719717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic Ace+7
Description: Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
Study: NCT04139395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECT
Description: Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.
Study: NCT04653103

Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: Biopsy of the liver to assess for Non-alcoholic steatohepatitis
Study: NCT03195699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Oral tablet
Study: NCT03172897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h (0.1 μg/kg per h) from study recruitment in the ICU for no more than 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h from study recruitment in the ICU for no more than 72 hours.
Study: NCT00910858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 5-mg capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
Study: NCT02872402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Women who are still breastfeeding at the first postpartum visit will be encouraged to pursue. References to local breastfeeding supporting groups will be done, if needed. The intervention will be conducted in order to reach recommendations for food servings and nutrient needs. Particular attention will be paid to increase fruits, vegetables, fish and whole grains intake, and decrease added sugars and high fat meat/dairy products. Women will be strongly encouraged to be active at least 150 min/week. They will be provided with targeted strategies for exercising, types of exercises and tips for including physical activity into the daily routine as well as fun exercises for the whole family.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control lifestyle intervention
Description: Participants in the control group will receive standard lifestyle recommendations in the form of written information at each visit.
Study: NCT02844374

Intervention type: OTHER
Group type: OTHER
Intervention: Functional stereotaxic exploration
Description: Visual analysis : in order to define the level of cortical resections. Epileptogenic maps : calculated for each crisis and for all crisis in general. Connectivity maps : calculated for each site stimulated at low-frequency. Post-operative evaluation : in order to assess the extent of resection.
Study: NCT00711503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) \[13\] at a dose of 100 mg once daily by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
Study: NCT02025582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape of the Ankle
Description: Tibialis anterior facilitation/ gastrocnemius inhibition: Taping to be worn 3-5 days and repeated x 1
Study: NCT01214330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-Collected Cervical Pap Smear
Description: Patient-Collected Cervical Papanicolaou Smear
Study: NCT02832908

Intervention type: OTHER
Group type: OTHER
Intervention: Change from semi-seated position to supine
Description: from semi-seated position (30°) to lying position
Study: NCT01767441

Intervention type: PROCEDURE
Intervention: Roux-en-Y-gastric bypass
Description: Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb

Intervention type: PROCEDURE
Intervention: laparoscopic adjustable gastric banding
Description: Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
Study: NCT00616148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP3089
Description: Oral dosage form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00277238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG10101
Description: CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG10101
Description: CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG10101
Description: CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
Study: NCT03253653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterpipe smoking
Description: In a repeated measures design, 50 adult male and female exclusive WP tobacco smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices as follows: 1) using room temperature water in the WP jar, 2) adding ice cubes to the water in the WP jar, and 3) using a charcoal-free electronic WP head to heat the tobacco. Six Spot first morning urine samples will be provided by participants. Two urine samples per each of the 3 smoking sessions. Urine samples will be provided on the day of the WP tobacco smoking session and the following day. Physiological measures will be taken at Baseline during the office visit and before and after each of the 3 WP tobacco smoking sessions.
Study: NCT02866292

Intervention type: OTHER
Intervention: Pelvic floor muscle and sexual function evaluation
Description: PFM evaluation was performed by vaginal palpation and vaginal squeeze pressure. During vaginal palpation the physiotherapist introduced the index and middle fingers about 4cm inside the vagina, and requested to hold the maximum contraction of the PFM. Muscle function was classified by the Oxford Scale Modified.~The vaginal squeeze pressure was measured through Perineometer.To obtain the measurements, the subjects remained positioning and vaginal sensor was introduced into the vaginal cavity. The women were oriented and motivated verbally to perform three voluntary maximal contractions sustained for five seconds and one minute interval between them.~Sexual function was evaluated by the Female Sexual Function Index (FSFI) questionnaire. The questionnaire consists of 19 multiple-choice questions, which involves six sexual response domains: desire, arousal, lubrication, orgasm, satisfaction and pain.

Intervention type: OTHER
Intervention: Pelvic floor muscle and sexual function evaluation
Description: PFM evaluation was performed by vaginal palpation and vaginal squeeze pressure. During vaginal palpation the physiotherapist introduced the index and middle fingers about 4cm inside the vagina, and requested to hold the maximum contraction of the PFM. Muscle function was classified by the Oxford Scale Modified.~The vaginal squeeze pressure was measured through Perineometer.To obtain the measurements, the subjects remained positioning and vaginal sensor was introduced into the vaginal cavity. The women were oriented and motivated verbally to perform three voluntary maximal contractions sustained for five seconds and one minute interval between them.~Sexual function was evaluated by the Female Sexual Function Index (FSFI) questionnaire. The questionnaire consists of 19 multiple-choice questions, which involves six sexual response domains: desire, arousal, lubrication, orgasm, satisfaction and pain.
Study: NCT01994434

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Decompression of the ulnar nerve
Description: Surgical decompression of the Guyon's canal and ganglion excision
Study: NCT00771719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Description: Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days